オプションチェーンは、CEL-SCIの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、CEL-SCIの市場センチメントを評価します。.

CEL-SCI (AMEX:CVM) 株価情報, オプションチェーン

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

General

Cel-Sci shares are trading higher after the company announced it is in the final stages of its 212-patient confirmatory registration study of Multikine.

Biotech

CEL-SCI Announces Final Stages For 212-Patient Confirmatory Registration Study Of Multikine In Advanced Head And Neck Cancer To Confirm Phase 3 Efficacy And Safety Results

CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.
"CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of data from the largest Phase 3 head and neck cancer study ever performed, with statistically significant evidence that our drug can successfully fight cancer and extend lives in head and neck cancer," stated CEL-SCI CEO, Geert Kersten. "We hope to deliver a new standard of care to patients while substantially transforming our company's valuation to reflect what we believe to be the intrinsic value of our cancer drug. The statistical analysis shows that our very soon to be initiated small confirmatory Registration Study has a very high chance of success and we will have indications of efficacy as early as 2026. Should the pre-surgical tumor responses mirror what we saw in the Phase 3 data, we believe we will be on the path for accelerated and/or conditional approval for Multikine next year."

News

CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.75 percent increase over losses of $(0.16) per share from the same period last year.

Earnings

Earnings Beats

CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.2% to $2.71 during Monday's pre-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock moved upwards by 57.47% to $0.31. The market value of their outstanding shares is at $10.2 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 42.43% to $0.53. The company's market cap stands at $29.1 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares rose 39.39% to $4.6. The market value of their outstanding shares is at $8.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 17.64% to $1.8. The company's market cap stands at $7.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 15.29% to $0.63. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares declined by 40.0% to $8.06 during Monday's pre-market session. The company's market cap stands at $24.3 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock decreased by 29.97% to $0.42. The company's market cap stands at $26.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.64% to $0.38. The company's market cap stands at $27.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 12.48% to $3.93. The company's market cap stands at $203.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock fell 10.66% to $0.53. The company's market cap stands at $314.9 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock declined by 9.91% to $0.19. The market value of their outstanding shares is at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

CPHI

MRNS

OTRK

PLRZ

QNRX

SENS

TRAW

VINC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.7% on Monday.
The Dow traded down 0.67% to 42,702.02 while the NASDAQ fell 0.73% to 19,578.50. The S&amp;P 500 also fell, dropping, 0.72% to 5,928.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares rose by 0.2% on Monday.
In trading on Monday, consumer discretionary shares dipped by 1.2%.
Top Headline
U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 5% to $6.69. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 12% to $9.27. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 7% to $14.48. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertical Aerospace Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares dropped 15% to $13.20. The company recently announced it has finalized an investment agreement for up to $50 million in new funding.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 41% to $7.92. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 31% to $0.42. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded down 0.6% at $2,616.00.
Silver traded down 2% to $29.385 on Monday, while copper fell 0.8% to $4.0880.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.46%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.57%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 fell 0.35%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose six points to a reading of 3.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CTKB

EVTL

HSAI

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 100 points on Monday.
The Dow traded down 0.61% to 42,725.52 while the NASDAQ fell 0.58% to 19,608.47. The S&amp;P 500 also fell, dropping, 0.59% to 5,935.35.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.6% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.2%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 6% to $6.79. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 13% to $9.36. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 9% to $14.69. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares dropped 20% to $56.60.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.25. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 28% to $0.4301. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.32 while gold traded down 0.6% at $2,615.80.
Silver traded down 1.5% to $29.505 on Monday, while copper fell 0.7% to $4.0930.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index rose 0.01%, while London's FTSE 100 fell 0.62%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Equities

QMCO

Crude Oil Gains 1%; Chicago PMI Falls In December

WIIM

Cel-Sci shares are trading lower after the company announced a $5 million public offering of 16.13 million shares.

U.S. stocks traded lower this morning, with the Dow Jones dipping around 600 points on Monday.
Following the market opening Monday, the Dow traded down 1.40% to 42,390.68 while the NASDAQ fell 1.53% to 19,419.90. The S&amp;P 500 also fell, dropping, 1.43% to 5,885.51.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.3% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.1%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Intrusion Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares shot up 192% to $6.34.</li>
<li>Shares of Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>)got a boost, surging 210% to $0.7556.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares were also up, gaining 186% to $1.1600.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares dropped 40% to $2.71.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.15. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 35% to $0.3923. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $71.24 while gold traded down 0.4% at $2,622.40.
Silver traded down 1% to $29.680 on Monday, while copper fell 0.6% to $4.0985.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX fell 0.4% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.6%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

INTZ

WATT

US Stocks Open Lower; Dow Tumbles 600 Points

Cel-Sci Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares are trading lower premarket on Monday.
On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42716897/cel-sci-announces-pricing-of-5-million-public-offering" rel="noreferrer noopener">warrants at $0.31 per share</a>.
The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions.
The company plans to use proceeds to support the development of Multikine, general <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42711737/cel-sci-announces-proposed-public-offering-of-common-stock" rel="noreferrer noopener">corporate purposes, and working capital</a>.
Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42461679/cel-sci-highlights-biological-rationale-for-the-use-of-multikine-in-the-confirmatory-registration-" rel="noreferrer noopener">head and neck cancer</a>.
The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial.
Price Action: CVM shares are down 29.9% at $0.4204 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42719119/us-stock-futures-slip-after-fridays-fall-santa-rally-in-doubt-analyst-calls-it-a-bit-of-profit-taking" target="_blank" rel="noreferrer noopener">US Stock Futures Slip After Friday&#8217;s Fall: &#8216;Santa Rally&#8217; In Doubt? Analyst Calls It A Bit Of Profit-Taking</a></li>
</ul>
Photo via Shutterstock.

Offerings

Small Cap

What's Going On With Cel-Sci Shares Premarket On Monday?

U.S. stock futures declined on Monday after ending <a href="https://www.benzinga.com/24/12/42711387/wall-streets-santa-rally-at-risk-palantir-dethrones-nvidia-consumer-confidence-pulls-back-this-week-in-the-markets">lower </a>on Friday. All four index futures slipped in trade.
Although ‘Santa Rally' has not picked up pace despite rising over 1% on Christmas Eve, the S&amp;P 500 index is on its way to registering a robust 20% plus return for the second consecutive year in 2024.
The 10-year and two-year Treasury notes yielded 4.59% and 4.30%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025, FOMC meeting was at 88.8%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.18%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.02%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.23% to $593.66 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.20% to $521.43, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stock markets experienced a <a href="https://www.benzinga.com/news/earnings/24/12/42717902/dow-dips-over-300-points-but-records-weekly-gain-greed-index-remains-in-fear-zone">lower</a> close on Friday as major indices retreated following gains on a weekly basis. The Dow Jones Industrial Average declined by over 300 points, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) suffered losses.
The Dow Jones Industrial Average closed at 42,992.21, down approximately 0.77%, whereas, the S&amp;P 500 and Nasdaq Composite also experienced declines, falling by 1.11% and 1.49%, respectively.
All sectors within the S&amp;P 500 ended the day in negative territory. Consumer discretionary, communication services, and information technology sectors recorded the most significant losses.
On the economic front, U.S. wholesale inventories decreased by 0.2% in November. The U.S. trade deficit in goods widened to $102.86 billion.
Despite Friday&#8217;s losses, major indices still recorded positive returns for the week. The Dow Jones gained approximately 0.4%, ending a three-week losing streak. The S&amp;P 500 added 0.7%, and the Nasdaq rose by about 0.8%.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.49%</td>
<td>19,722.03</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.11%</td>
<td>5.970.84</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.77%</td>
<td>42,992.21</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.56%</td>
<td>2,244.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Chamath Palihapitiya, the billionaire investor, and former Facebook executive, explained in an X post that greater concentration in a few stocks increases the risks of investing.
He highlighted the inequality in the weight of the stocks within the S&amp;P 500 index and said, "If there is any market volatility, the lack of diversification could cause massive impairment."
Kevin Gordon, the director and senior investment strategist at Charles Schwab shared a graphic showing the top ten stocks in the S&amp;P 500 represent 40% of the index market capitalization.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This needs to be fixed or it will end in disaster. Why? Average Americans buy S&amp;P 500 index ETFs, in part, because Buffett told them to. They were told they would pay very little and get diversification in the 500 best companies on earth to ride out storms. But as… <a href="https://t.co/YEYhjvrSg7">https://t.co/YEYhjvrSg7</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1873144394100187263?ref_src=twsrc%5Etfw">December 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As the ‘Magnificent Seven&#8217; stock led the market lower on Friday, Louis Navellier of Navellier &amp; Associates in his note said, "The Santa Claus rally is in serious doubt now." But he quipped that "It certainly appears to be a bit of profit-taking."
Reinstalling confidence among investors Navellier added that Friday's selloff should not be worrisome and the ‘B team' of traders were getting rid of their inventory before the weekend.
"Investors shouldn&#8217;t worry about the sell-off – it&#8217;s just what we call inventory cleaning. But there is a sell-off today, and if you did want to buy, it's not a bad time to nibble. Normally, we rally going into New Year&#8217;s, and we normally rally in the new year. So, if we don&#8217;t, it means we have to wait until the A team comes back, which will of course be after the New Year&#8217;s holiday," he added.
The 10-year Treasury yield hit 4.631% during Friday's session, which was its highest level since May 30, 2024. However, it is currently yielding 4.59% on Monday.
Talking about the spiking yields, Ed Yardeni, the president at Yardeni Research said in a note "The Bond Vigilantes are sending a loud warning message. They aren&#8217;t convinced Donald Trump, the new sheriff coming to town, will maintain fiscal law and order any better than the old sheriff. They are also losing their confidence in Jerome Powell, the deputy in charge of monetary law and order."
According to Navellier, "The bond vigilantes have been pushing the narrative that the Trump tariffs are going to be inflationary, but the reality is that a strong U.S. dollar causes the prices of commodities and imported goods to decline."
Yardeni, in his note, mentioned that a pullback in the markets may have already started. "We still think that the 10-year yield should trade around 4.50% plus/minus 25bps in 2025. But we can&#8217;t rule out a move back up to last year&#8217;s high of 5.00% early next year. That&#8217;s another reason why we expect a stock market pullback/correction that might have started already. The S&amp;P 500 peaked at a record 6090.27 on Dec. 6," he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points will be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Monday, Chicago Business Barometer (PMI) data for December will announced at 9:45 a.m., ET.</li>
</ul>
<ul>
<li>November's pending home sales data will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, November's S&amp;P Case-Shiller home price index for 20 cities will be announced at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>No data is slated to be released on Wednesday, Jan. 1, owning to a New Year's holiday.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Dec. 28 will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Construction spending data for November will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, ISM manufacturing data for December will be announced at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down 43.34% in premarket trade after it priced its $5 million public offering of 16.13 million common shares at 31 cents per share.</li>
</ul>
<ul>
<li>CCSC Technology International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) was up 31.71% after its earnings on Friday. Its revenue surged by 22.9% year-over-year to $9.2 million for the third quarter.</li>
</ul>
<ul>
<li>Citius Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) was down 16.58% after reporting a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share.</li>
</ul>
<ul>
<li>Genius Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) was up 15.81% in premarket after posting first-half revenue of $4.9 million, down from $11.8 million in the year-ago period. Its net assets surged 177% to $54.6 million from $19.7 million as of Dec. 31, 2023.</li>
</ul>
<ul>
<li>Intrusion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) was up 125.93% in premarket after Dow Newswire reported Streeterville Capital has acquired a 9.8% stake in the company.</li>
</ul>
<ul>
<li>Amplitech Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) was up 24.17% as it raised $5.8 million in gross proceeds for the company before fees and expenses were deducted. It was a direct offer of 1,871,000 shares of common stock at $3.10 per share to institutional investors.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.18% to hover around $70.47 per barrel.
The gold spot index was down by 0.25% to $2,625.56 per ounce. The Dollar Index was down 0.05% to 107.947 level.
Asian markets were mostly lower on Monday as Hong Kong&#8217;s Hang Seng, Japan&#8217;s Nikkei 225, Australia&#8217;s ASX 200, and South Korea&#8217;s Kospi declined. Whereas, China&#8217;s CSI 300 ended higher. European markets were mixed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678368/sp-500-hits-57-all-time-highs-in-record-breaking-2024-magnificent-7-drive-30-of-nasdaqs-surge">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq&#8217;s Surge</a> </li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Economics

Pre-Market Outlook

AMPG

CCTG

CTXR

NVDA

TSLA

US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking

Shares of Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) rose sharply in today's pre-market trading after the company announced a binding term sheet for a strategic <a href="https://www.benzinga.com/quote/VINC/news">merger with Oqory, Inc</a>.
Vincerx Pharma shares jumped 63.9% to $0.3180 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) gained 120% to $4.76 in pre-market trading after surging around 380% on Friday.</li>
<li>Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) gained 98.4% to $2.58 in pre-market trading after gaining 27% on Friday.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) rose 78.7% to $0.7237 in pre-market trading.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) gained 54.2% to $2.19 in pre-market trading after gaining 3% on Friday. Castellum announced the pricing of a previously announced stock offering of 4,355,000 shares at 85 cents per share for gross proceeds of approximately $3.7 million.</li>
<li>Solidion Technology Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) gained 51.2% to $1.06 in pre-market trading after surging around 69% on Friday.</li>
<li>Aeries Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) gained 41.4% to $1.24 in pre-market trading after falling around 5% on Friday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) rose 31.6% to $3.21 in pre-market trading after climbing around 28% on Friday.</li>
<li>Palladyne AI Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) gained 22.7% to $14.45 in pre-market trading after gaining over 61% on Friday.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 15% to $2.45 in pre-market trading after adding 9% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) fell 43.3% to $0.34 in pre-market trading as the company priced its $5 million public offering 16.13 million common shares at 31 cents per share.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 33.1% to $1.07 in pre-market trading after surging around 82% on Friday.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) declined 27.5% to $0.43 in pre-market trading after jumping around 267% on Friday.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares dipped 16.5% to $3.07 in pre-market trading. Citius Pharmaceuticals reported a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share.</li>
<li>Hudson Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) shares fell 15.5% to $11.31 in pre-market trading.</li>
<li>Tamboran Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>) fell 14.4% to $16.00 in pre-market trading.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares fell 14.4% to $1.97 in pre-market trading after jumping 32% on Friday.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) fell 13.4% to $13.01 in today's pre-market trading.</li>
<li>HarborOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) dipped 11.5% to $10.60 in pre-market trading.</li>
<li>Sprott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SII#NYSE">SII</a>) fell 6.4% to $39.31 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>

Advanced Environmental Recycling Technologies

AERT

AILE

HONE

HSON

KORE

LITM

NATR

PDYN

REKR

SLDP

Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>CEL-SCI Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) said it priced its $5 million public offering 16.13 million common shares at 31 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. CEL-SCI shares fell 8.6% to $0.55 in the after-hours trading session.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) posted a net loss of $0.7 million for the six months ended Sept. 30, versus a year-ago net income of $0.4 million. Its revenue surged by 22.9% year-over-year to $9.2 million during the period. CCSC Technology International shares jumped 49.4% to $2.45 in after-hours trading.</li>
<li>Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) announced that Pamela Coe, a member of the Board of Directors, will be retiring from the Luna board. Luna Innovations shares fell 5.5% to $2.05 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) reported a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share. Citius Pharmaceuticals shares slipped 1.9% to $1.0207 in the after-hours trading session.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) posted first-half revenue of $4.9 million, down from $11.8 million in the year-ago period. Its net assets surged 177% to $54.6 million from $19.7 million as of Dec. 31, 2023. Genius Group shares jumped 11.6% to $0.72 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo courtesy: Shutterstock

LUNA

CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday

Reported Earlier, CEL-SCI Prices $5M Public Offering 16.13M Common Shares At $0.31/Share

<ul>
<li>Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery</li>
<li>Factors supporting the go-ahead for the 212-person registration study in the target population include:
<ul>
<li>Multikine led to significant rates of tumor regression</li>
<li>Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit</li>
<li>Target population is likely to show significant survival prolongation in the confirmatory study</li>
</ul>
</li>
<li>Confirmatory study target population selection is based on:
<ul>
<li>Strong statistical significance in a large subgroup of 114 patients</li>
<li>Subgroup analysis was pre-defined in the statistical analysis plan (SAP)</li>
<li>Strong biological rationale for the results based on Multikine's mechanism of action (MOA)</li>
</ul>
</li>
</ul>
CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today highlights strong biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study.

CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer

<a href="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf" title="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf">https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf</a>

Analyst Ratings

Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation

CEL-SCI And U.S. FDA Approve Use Of PD-L1 Biomarker To Select Head And Neck Cancer Patients For Multikine Registration Study, Targeting Low PD-L1 Expression Patients With 5-Year Survival Rates Of 73%; Study Set To Begin Q1 2025

<ul>
<li>Oncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low PD-L1 expression</li>
<li>Multikine has shown survival benefit and favorable safety profile in a randomized controlled Phase 3 study of treatment naïve resectable locally advanced head and neck cancer patients with low PD-L1 expression</li>
<li>Multikine has potential as a combination drug with current checkpoint inhibitors such as Keytruda which is projected to be the top selling drug in the world with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.statista.com%2Fstatistics%2F973523%2Ftop-drugs-by-year-on-year-sales-increase%2F%23%3A%7E%3Atext%3DKeytruda%2520is%2520projected%2520to%2520be%2Cthan%252027%2520billion%2520U.S.%2520dollars.&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=%2427+billion&amp;index=1&amp;md5=df83c0b582408bd76ecc1c7fee8d4c20">$27 billion</a> in 2024 sales</li>
<li>To the Company's knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=2&amp;md5=68ef23ce754be1ace196803245ed0a4a">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced the potential positive impact on the clinical development of its immunotherapy Multikine&#xAE; (Leukocyte Interleukin, Injection)&#x2A; resulting from a recent U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fadvisory-committees%2Fadvisory-committee-calendar%2Fseptember-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=meeting&amp;index=3&amp;md5=ae1bd361b36091a7bf7484e1dbf4a939">meeting</a>, a public forum.
FDA advisory committees provide independent expert advice to the FDA on the safety and effectiveness of new and marketed drugs and help the agency make sound and informed decisions. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.
The September 27, 2024 ODAC meeting evaluated the use of checkpoint inhibitors on patients with various cancers. PD-L1 is the biomarker most often used for patient selection for checkpoint inhibitors, the most successful class of cancer drugs including Keytruda and Opdivo. The FDA sought the ODAC's opinion on the following:
<ul>
<li>adequacy of PD-L1 expression as a predictive biomarker for patient selection in this patient population</li>
<li>differing risk-benefit assessments in different subpopulations defined by PD-L1 expression</li>
<li>adequacy of the cumulative data to restrict the approvals of immune checkpoint inhibitors based on PD-L1 expression</li>
</ul>
Following a thorough analysis of peer-reviewed published data, the panel of experts on the ODAC voted 10-2 and 11–1 against the risk-benefit profile for PD-L1 inhibitors in various cancers in two separate votes. Most ODAC members expressed concerns about the lack of benefit demonstrated for patients with low PD-L1 expression, while some members pointed to evidence that the use of the immune checkpoint inhibitors may add unnecessary toxicities for patients while also increasing financial burdens on patients.
Checkpoint inhibitors were an estimated $48 billion global market in 2023, with PD-L1 inhibitors representing 73% of the market. Current labeling for approved checkpoint inhibitors in the indications evaluated by the FDA's ODAC include broad approvals for all patients, regardless of PD-L1 expression.

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A Randomized Controlled Phase 3 Study Of Treatment Naïve Resectable Locally Advanced Head And Neck Cancer Patients With Low PD-L1 Expression

Contracts

CEL-SCI Reveals Renewed Collaboration With Ergomed Clinical Research For Its Upcoming FDA Confirmatory Registration Study Of Multikine In Head And Neck Cancer

<ul>
<li>5-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who met the CEL-SCI confirmatory Registration Study target population criteria and were deemed at low risk for recurrence, therefore not recommended per NCCN guidelines to receive chemotherapy post-surgery</li>
<li>Data provide further evidence that the selection criteria for CEL-SCI's upcoming confirmatory Registration Study may yield improved clinical outcomes</li>
<li>Future advances in diagnostic technologies that improve patient selection, such as PET scans (which will be used in the confirmatory study), may further optimize patient selection and Multikine's already strong efficacy results from the current 5-year Overall Survival at 73% up into the 82% range</li>
<li>Clear unmet need: the 5-year survival rate remains below 50% in locally advanced resectable head and neck cancer patients who receive standard of care only</li>
</ul>

Health Care

CEL-SCI Reported New Data From Its Concluded Phase 3 Study Of Multikine (Leukocyte Interleukin, Injection) Presented At The European Society For Medical Oncology, Showing An Increased 5-year Survival Rate To 82.6% In Locally Advanced Resectable Head & Neck Cancer Patients

Press Releases

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Comments

CEL-SCI

CEL-SCI (CVM) オプション

CEL-SCI (AMEX:CVM) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル